无明确指征在华法林治疗中加用阿司匹林与出血及其他不良事件的关联
该注册队列研究纳入美国密歇根州6家抗凝门诊2010年1月1日至2017年12月31日因心房颤动或静脉血栓栓塞症接受华法林治疗的成人,排除近期心肌梗死或瓣膜置换史。6539例患者中2453例(37.5%)无明确指征仍联合阿司匹林。倾向评分匹配后各1844例分析显示,1年时联合组总体出血累积发生率26.0%(95%CI 23.8%-28.3%)vs 单药组20.3%(95%CI 18.3%-22.3%),大出血5.7%(95%CI 4.6%-7.1%)vs 3.3%(95%CI 2.4%-4.3%),因出血急诊就诊13.3%(95%CI 11.6%-15.1%)vs 9.8%(95%CI 8.4%-11.4%),因出血住院8.1%(95%CI 6.8%-9.6%)vs 5.2%(95%CI 4.1%-6.4%),差异均显著(P<.001或P=.001);血栓事件率相似,联合组2.3%(95%CI 1.6%-3.1%)vs 单药组2.7%(95%CI 2.0%-3.6%),P=.40。3年随访及敏感性分析结果相似。作者认为需进一步研究以分层哪些患者可能从华法林抗凝期间加用阿司匹林获益,临床医生应审慎选择联合治疗患者。
要点
- 在因心房颤动或静脉血栓栓塞症接受华法林治疗且无明确阿司匹林指征的患者中,37.5%(2453/6539)仍联合使用阿司匹林。
- 倾向评分匹配后1年,联合组总体出血累积发生率26.0%(95%CI 23.8%-28.3%)高于单药组20.3%(95%CI 18.3%-22.3%),P<.001。
- 1年大出血联合组5.7%(95%CI 4.6%-7.1%)高于单药组3.3%(95%CI 2.4%-4.3%),P<.001。
- 1年因出血急诊就诊联合组13.3%(95%CI 11.6%-15.1%)高于单药组9.8%(95%CI 8.4%-11.4%),P=.001;因出血住院联合组8.1%(95%CI 6.8%-9.6%)高于单药组5.2%(95%CI 4.1%-6.4%),P=.001。
- 1年血栓事件率联合组2.3%(95%CI 1.6%-3.1%)与单药组2.7%(95%CI 2.0%-3.6%)相似,P=.40。
适用人群与场景
- 在密歇根州6家抗凝门诊注册的成人,2010年1月1日至2017年12月31日因心房颤动或静脉血栓栓塞症接受华法林治疗,且无近期心肌梗死记录或瓣膜置换史。
处置流程与药物剂量
- 对于因心房颤动或静脉血栓栓塞症接受华法林且无明确阿司匹林治疗指征(如机械心脏瓣膜置换、近期经皮冠状动脉介入治疗或急性冠脉综合征)的患者,联合阿司匹林与华法林单药相比与出血增加相关,血栓事件率相似;作者认为临床医生应审慎选择联合治疗患者。
研究设计与关键结果
- 研究类型为注册队列研究,纳入6539例患者(3326例男性[50.9%];平均[SD]年龄66.1[15.5]岁),其中2453例(37.5%)无明确指征使用阿司匹林联合华法林。
- 倾向评分匹配后各1844例分析:1年总体出血累积发生率联合组26.0%(95%CI 23.8%-28.3%)vs 单药组20.3%(95%CI 18.3%-22.3%),P<.001。
- 1年大出血联合组5.7%(95%CI 4.6%-7.1%)vs 单药组3.3%(95%CI 2.4%-4.3%),P<.001。
- 1年因出血急诊就诊联合组13.3%(95%CI 11.6%-15.1%)vs 单药组9.8%(95%CI 8.4%-11.4%),P=.001;因出血住院联合组8.1%(95%CI 6.8%-9.6%)vs 单药组5.2%(95%CI 4.1%-6.4%),P=.001。
- 1年血栓事件累积发生率联合组2.3%(95%CI 1.6%-3.1%)vs 单药组2.7%(95%CI 2.0%-3.6%),P=.40。
- 3年随访期间及敏感性分析中,上述结果持续存在。
证据类型、等级与局限
- 证据类型:注册队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于因心房颤动或静脉血栓栓塞症接受华法林且无明确阿司匹林指征的患者,联合阿司匹林与华法林单药相比观察到出血增加、血栓事件率相似;作者认为需进一步研究以更好分层哪些患者可能从华法林抗凝期间加用阿司匹林获益,临床医生应审慎选择联合治疗患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is not clear how often patients receive aspirin (acetylsalicylic acid) while receiving oral anticoagulation with warfarin sodium without a clear therapeutic indication for aspirin, such as a mechanical heart valve replacement, recent percutaneous coronary intervention, or acute coronary syndrome. The clinical outcomes of such patients treated with warfarin and aspirin therapy compared with warfarin monotherapy are not well defined to date.
OBJECTIVE: To evaluate the frequency and outcomes of adding aspirin to warfarin for patients without a clear therapeutic indication for combination therapy.
DESIGN, SETTING, AND PARTICIPANTS: A registry-based cohort study of adults enrolled at 6 anticoagulation clinics in Michigan (January 1, 2010, to December 31, 2017) who were receiving warfarin therapy for atrial fibrillation or venous thromboembolism without documentation of a recent myocardial infarction or history of valve replacement.
EXPOSURE: Aspirin use without therapeutic indication.
MAIN OUTCOMES AND MEASURES: Rates of any bleeding, major bleeding events, emergency department visits, hospitalizations, and thrombotic events at 1, 2, and 3 years.
RESULTS: Of the study cohort of 6539 patients (3326 men [50.9%]; mean [SD] age, 66.1 [15.5] years), 2453 patients (37.5%) without a clear therapeutic indication for aspirin were receiving combination warfarin and aspirin therapy. Data from 2 propensity score-matched cohorts of 1844 patients were analyzed (warfarin and aspirin vs warfarin only). At 1 year, patients receiving combination warfarin and aspirin compared with those receiving warfarin only had higher rates of overall bleeding (cumulative incidence, 26.0%; 95% CI, 23.8%-28.3% vs 20.3%; 95% CI, 18.3%-22.3%; P < .001), major bleeding (5.7%; 95% CI, 4.6%-7.1% vs 3.3%; 95% CI, 2.4%-4.3%; P < .001), emergency department visits for bleeding (13.3%; 95% CI, 11.6%-15.1% vs 9.8%; 95% CI, 8.4%-11.4%; P = .001), and hospitalizations for bleeding (8.1%; 6.8%-9.6% vs 5.2%; 4.1%-6.4%; P = .001). Rates of thrombosis were similar, with a 1-year cumulative incidence of 2.3% (95% CI, 1.6%-3.1%) for those receiving combination warfarin and aspirin therapy compared with 2.7% (95% CI, 2.0%-3.6%) for those receiving warfarin alone (P = .40). Similar findings persisted during 3 years of follow-up as well as in sensitivity analyses.
CONCLUSIONS AND RELEVANCE: Compared with warfarin monotherapy, receipt of combination warfarin and aspirin therapy was associated with increased bleeding and similar observed rates of thrombosis. Further research is needed to better stratify which patients may benefit from aspirin while anticoagulated with warfarin for atrial fibrillation or venous thromboembolism; clinicians should be judicious in selecting patients for combination therapy.
参考来源
- Schaefer JK, Li Y, Gu X, et al. Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. JAMA Intern Med. 2019. PMID: 30830172. doi:10.1001/jamainternmed.2018.7816
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。